Sinonasal Cancer Clinical Trials

6 recruitingLast updated: May 13, 2026

There are 6 actively recruiting sinonasal cancer clinical trials across 2 countries. Studies span Phase 2, Phase 1, Not Applicable. Top locations include Atlanta, Georgia, United States, Lexington, Kentucky, United States, Boston, Massachusetts, United States. Updated daily from ClinicalTrials.gov.


Sinonasal Cancer Trials at a Glance

6 actively recruiting trials for sinonasal cancer are listed on ClinicalTrialsFinder across 6 cities in 2 countries. The largest study group is Phase 2 with 3 trials, with the heaviest enrollment activity in Atlanta, Lexington, and Boston. Lead sponsors running sinonasal cancer studies include Emory University, National Cancer Institute (NCI), and Glenn J. Hanna.

Browse sinonasal cancer trials by phase

Treatments under study

About Sinonasal Cancer Clinical Trials

Looking for clinical trials for Sinonasal Cancer? There are currently 1 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Sinonasal Cancer trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Sinonasal Cancer clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 16 of 6 trials

Recruiting
Phase 2

Testing the Addition of Cemiplimab (REGN2810) to Chemotherapy Treatment Given Prior to Surgery in Patients With Sinonasal Squamous Cell Carcinoma

Sinonasal Squamous Cell CarcinomaStage III Sinonasal Cancer AJCC v8Stage IVA Sinonasal Cancer AJCC v8+1 more
National Cancer Institute (NCI)108 enrolled1 locationNCT07281417
Recruiting
Not Applicable

Remote Audiometry to Monitor for Treatment-Related Hearing Loss in Patients With H&N SCC Receiving Cisplatin and/or Radiation

Head and Neck Squamous Cell CarcinomaMetastatic Head and Neck Squamous Cell CarcinomaStage IV Cutaneous Squamous Cell Carcinoma of the Head and Neck AJCC v8+30 more
Emory University118 enrolled1 locationNCT06662058
Recruiting
Phase 1

Testing the Addition of Ipatasertib to Usual Chemotherapy and Radiation for Head and Neck Cancer

Locally Advanced Head and Neck Squamous Cell CarcinomaClinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8Stage III Hypopharyngeal Carcinoma AJCC v8+23 more
National Cancer Institute (NCI)46 enrolled18 locationsNCT05172245
Recruiting
Phase 1

TMV Vaccine Therapy Alone and With Pembrolizumab for the Treatment of Recurrent and/or Metastatic Head and Neck Squamous Cell Cancer

Metastatic Head and Neck Squamous Cell CarcinomaStage IV Cutaneous Squamous Cell Carcinoma of the Head and Neck AJCC v8Recurrent Head and Neck Squamous Cell Carcinoma+20 more
Emory University40 enrolled2 locationsNCT06868433
Recruiting
Phase 2

Lovastatin and Pembrolizumab for the Treatment of Patients With Recurrent or Metastatic Head and Neck Cancer, LAPP Trial

Metastatic Head and Neck Squamous Cell CarcinomaRecurrent Head and Neck Squamous Cell CarcinomaClinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8+19 more
Emory University28 enrolled2 locationsNCT06636734
Recruiting
Phase 2

Toripalimab With Chemotherapy for Sinus Cancer

Squamous Cell CarcinomaSinonasal Undifferentiated CarcinomaLocally Advanced Head-and-Neck Cancer+2 more
Glenn J. Hanna20 enrolled2 locationsNCT06940180